Biomerix Corporation today announced that the United States Patent and Trademark Office (USPTO) has granted a patent for its proprietary biomaterial platform technology titled "Reticulated elastomeric matrices, their manufacture and use in implantable devices." The Company's platform technology, the Biomerix Biomaterial™ is a non-resorbable reticulated, polycarbonate polyurethane-urea, consisting of an open-cell, three-dimensional, interconnected tissue scaffold. The novel structure of the biomaterial translates into an ability to support predictable, organized fibrovascular tissue ingrowth and remodeling.
The Biomerix Biomaterial is designed to play a role similar to the body's extracellular matrix (ECM), through the main phases of inflammation, proliferation, and remodeling. Benefits of the Biomerix Biomaterial extend beyond medical device applications. The material's unique structure and chemistry impart differentiated benefits including high porosity, excellent resilience, long-term durability and superior chemical compatibility over current polymeric materials. It is these advantages that make the Biomerix Biomaterial a compelling alternative for potential industrial and consumer applications.
"Biomerix secured one of its most important intellectual property assets representing a significant milestone for our company and is the culmination of extensive research and development," stated Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation. "The scope of this technology is far reaching and has the potential to drive technological innovation across a broad spectrum of applications in the medical, industrial, and consumer industries."
How do different people define 'healthy eating'?